Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7593278 | 0.83 | PRSS1 (0.54) | HSP90AA1HSD17B10USP2HPGDCA2 | |
| SCHEMBL14951927 | 0.83 | HSP90AA1 (0.53) | HSP90AA1HSD17B10USP2HPGDCA2 | |
| SCHEMBL11707925 | 0.81 | HSP90AA1 (0.52) | HSP90AA1HSD17B10USP2HPGDCA2 | |
| SCHEMBL6822183 | 0.81 | HSP90AA1 (0.52) | HSP90AA1HSD17B10USP2HPGDCA2 | |
| SCHEMBL3822620 | 0.81 | HSP90AA1 (0.61) | HSP90AA1HSD17B10USP2HPGDCA2 | |
| SCHEMBL8294096 | 0.81 | CNR2 (0.53) | HSP90AA1HSD17B10USP2HPGDCA2 | |
| SCHEMBL4569291 | 0.81 | HSP90AA1 (0.52) | HSP90AA1HSD17B10USP2HPGDCA2 | |
| SCHEMBL10286193 | 0.80 | KMT2A (0.46) | HSD17B10USP2HPGDCA2CA1 | |
| SCHEMBL4491486 | 0.80 | HPGD (0.53) | HSP90AA1HSD17B10USP2HPGDCA2 | |
| SCHEMBL3192672 | 0.80 | CNR2 (0.65) | HSP90AA1HSD17B10USP2HPGDCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109251588-B | Inorganic nano material ink, preparation method and application thereof, and QLED device | TCL科技集团股份有限公司 | 2021-06-22 | — | — | CN | claimed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-109251588-B | Inorganic nano material ink, preparation method and application thereof, and QLED device | TCL科技集团股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-20200131335-A1 | SURFACE ACTIVE ADJUVANT | RHODIA OPERATIONS (FR) | 2020-04-30 | — | — | US | disclosed |
| EP-3612604-A1 | SURFACE ACTIVE ADJUVANT | Rhodia Operations (FR) | 2020-02-26 | — | — | EP | disclosed |
| WO-2020035124-A1 | SURFACE ACTIVE ADJUVANT FOR COATINGS | RHODIA OPERATIONS (FR) | 2020-02-20 | — | — | WO | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
| US-10472352-B2 | Rac inhibitors | Geneyus LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| WO-1995009158-A1 | TRICYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1995-04-06 | — | — | WO | disclosed |
| US-5328884-A | Salicylic acid salt,and amide or sulfonamide as developer | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| WO-1994007869-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
| US-5250108-A | Mixture of salicylic acid salt, amide and sulfonamide compounds | KANZAKI PAPER MANUFACTURING CO. LTD. (JP) | 1993-10-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0099329-B1 | DITHIO COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE | Zyma SA (CH) | 1990-10-31 | — | — | EP | disclosed |
| US-4946861-A | TREATMENT OF LIVER DISORDERS | ZYMA SA (CH) | 1990-08-07 | — | — | US | disclosed |
| US-4818765-A | TREATING LIVER, RESPIRATORY TRACT, VASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0099329-A1 | Dithio compounds, pharmaceutical preparations containing them and their use | Zyma SA (CH) | 1984-01-25 | — | — | EP | disclosed |
| US-3933869-A | Preparation of organic radiohalogen compounds | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | HSP90AA1 1309/4885HSD17B10 1819/4885USP2 2882/4885 |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | HSP90AA1 2529/4885HSD17B10 120/4885USP2 2478/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | HSP90AA1 1309/4885HSD17B10 1819/4885USP2 2882/4885 |
| US-10472352-B2 | Rac inhibitors | ARHGDIB, ARHGDIA, RAC1 | HSP90AA1 1039/4885HSD17B10 3190/4885USP2 3349/4885 |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | HSP90AA1 1309/4885HSD17B10 1819/4885USP2 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.